Yield10 Bioscience
Investment firm (auto-created from funding round data)
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Investment firm (auto-created from funding round data)
Yield10 Bioscience is an agricultural bioscience company developing advanced plant biotechnologies to enhance crop productivity and produce sustainable seed products from Camelina oilseed, targeting global food security, biofuels, omega-3 nutrition, and bioplastics.[1][2][5] It serves biofuel producers, aquafeed/petfood/nutritional markets, and the bioplastics industry by solving challenges in low-carbon feedstocks, omega-3 supply shortages, and biodegradable materials through engineered Camelina varieties that yield high-value oils, omega-3 fatty acids (EPA/DHA), PHA biopolymers, and protein-rich meal.[2][3][4] Despite promising field trials—like 50-acre omega-3 Camelina planting in Chile in 2023 and PHA prototyping—growth stalled amid financial woes, culminating in a Chapter 11 bankruptcy filing on December 6, 2024.[2][3]
Yield10 traces its roots to Metabolix, Inc., founded in 1992 by Oliver Peoples, Ph.D., and Anthony Sinskey, Ph.D., building on MIT research into engineering microbes and plants for polyhydroxyalkanoates (PHA) bioplastics and bio-based chemicals.[1][2][5] Metabolix pivoted to crop science in 2002, targeting PHB production in oilseeds and biomass crops like switchgrass and camelina, but faced growth impairments at high PHA levels, prompting a 2015 relaunch as Yield10 Bioscience with a new focus on photosynthetic efficiency via the "Smart Carbon Grid" and "T3 Platform" for yield boosts in canola, soybean, corn, and camelina.[1][4][5] Pivotal moments include USDA nonregulated status for CRISPR-edited camelina, Rothamsted Research's exclusive omega-3 license in recent years, and multi-acre field tests advancing commercialization.[3][5]
Yield10 rides sustainable ag-biotech and bioeconomy trends, amplifying photosynthesis/carbon use in crops amid climate-driven food/energy demands and omega-3 shortages from overfished oceans.[1][3] Timing aligns with biofuel mandates (e.g., low-CI SAF/RD), bioplastics push against petroleum, and gene-editing deregulation (CRISPR non-GMO status), favoring non-food Camelina on marginal lands for diversified farmer income.[3][4][5] It influences the ecosystem by pioneering multi-product seeds, bridging synthetic biology with row crops, and partnering (e.g., Rothamsted) to accelerate commercialization, though bankruptcy tempers near-term impact.[2][3]
Post-Chapter 11, Yield10's path hinges on restructuring to monetize Camelina assets—prioritizing omega-3 commercialization (elite varieties with agronomics/economics) and PHA scaling for feed/water treatment, potentially via asset sales or emergence leaner.[2][3][4] Trends like SAF demand, omega-3 sustainability regs, and CRISPR ag-advances favor it, but execution risks loom in a capital-scarce biotech climate. If restructured successfully, its platforms could evolve into licensed tech for majors, amplifying crop yield/food security impacts and tying back to its mission of metabolic breakthroughs for a bio-based future.[1][3]